Omisirge is the world’s 1st U.S. FDA approved product that is a expanded umbilical cord blood cell therapy.
It is also the only allogeneic stem cell therapy approved by the U.S. FDA on the basis of a global randomized Phase 3 trial.
Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress.
More: https://bioinformant.com/first-patient-receives-gamida-cells-omisirge/